meropenem sandoz
novartis new zealand ltd - meropenem trihydrate 570.78mg equivalent to meropenem 500 mg; - powder for injection - 500 mg - active: meropenem trihydrate 570.78mg equivalent to meropenem 500 mg excipient: nitrogen sodium carbonate - indicated for treatment, in adults and children, of lower respiratory tract infections.
meropenem 500 mg powder for solution for injection or infusion
venus pharma gmbh - meropenem - powder for solution for injection/infusion - 500 milligram(s) - carbapenems; meropenem
meropenem 500mg powder for solution for injection/infusion
hikma farmacêutica (portugal) s.a. - meropenem - powder for solution for injection/infusion - 500 milligram(s) - carbapenems; meropenem
meropenem 500mg powder for solution for injection or infusion
noridem enterprises limited - meropenem - powder for solution for injection/infusion - 500 milligram(s) - carbapenems; meropenem
meropenem apotex meropenem (as trihydrate) 500 mg powder for injection vial
arrotex pharmaceuticals pty ltd - meropenem trihydrate, quantity: 570.5 mg (equivalent: meropenem, qty 500 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: community acquired lower respiratory tract infection; hospital acquired lower respiratory tract infection; complicated urinary tract infection; febrile neutropenia; intra-abdominal and gynaecological (poly microbial) infections; complicated skin and skin structure infections; meningitis; septicaemia
meropenem apotex meropenem (as trihydrate) 1000 mg powder for injection vial
arrotex pharmaceuticals pty ltd - meropenem trihydrate, quantity: 1141 mg (equivalent: meropenem, qty 1000 mg) - injection, powder for - excipient ingredients: sodium carbonate - meropenem is indicated for treatment of the following infections, in adults and children (aged 3 months and over), when the causative organisms are known or suspected to be resistant to commonly used antibiotics: community acquired lower respiratory tract infection; hospital acquired lower respiratory tract infection; complicated urinary tract infection; febrile neutropenia; intra-abdominal and gynaecological (poly microbial) infections; complicated skin and skin structure infections; meningitis; septicaemia
meropenem 500 mg powder for solution for injection or infusion
acino ag - meropenem trihydrate - powder for solution for injection/infusion - 500 milligram(s) - carbapenems; meropenem
meropenem 1g powder for solution for injection vials
milpharm ltd - meropenem trihydrate - powder for solution for injection - 1gram
meropenem eugia 500 mg inj./inf. sol. (pwdr.) i.v. vial
eugia pharma (malta) ltd. - meropenem trihydrate 570,78 mg - eq. meropenem 500 mg - powder for solution for injection/infusion - 500 mg - meropenem trihydrate 570.78 mg - meropenem
meropenem accord 500 mg inj./inf. sol. (pwdr.) i.v. vial
accord healthcare b.v. - meropenem trihydrate 570,474 mg - eq. meropenem anhydrous 500 mg - powder for solution for injection/infusion - 500 mg - meropenem trihydrate 570.474 mg - meropenem